Mipomersen in Familial Hypercholesterolemia: an update on health-related quality of life and patient-reported outcomes

Vista sencilla de ítem
dc.date.accessioned2023-04-05T12:46:20Z
dc.date.available2023-04-05T12:46:20Z
dc.date.issued2022
dc.description.abstractFamilial hypercholesterolemia (FH) is an autosomal dominant condition that leads to significantly elevated low-density lipoprotein cholesterol (LDL-C) levels and an elevated risk for cardiovascular disease. Mipomersen is an antisense oligonucleotide inhibitor targeted to apolipoprotein B-100 (apoB-100) mRNA that is administered via subcutaneous injection. Once administered, mipomersen causes selective degradation of the apoB-100 mRNA and inhibition of protein translation. This ultimately results in substantial reductions in LDL-C and other lipoprotein levels. Mipomersen is approved for the treatment of homozygous FH. In this review, we discuss its mechanism, current evidence, limitations of use including adverse events, and impact on health-related quality of life. © 2022 Chambergo-Michilot et al.
dc.identifier.issn11766344
dc.identifier.urihttps://doi.org/10.2147/VHRM.S191965
dc.identifier.urihttp://146.190.124.33/handle/123456789/6060
dc.language.isoenges_ES
dc.publisherDove Medical Press Ltdes_ES
dc.sourceRevista de la Asociación Española de Especialistas en Medicina del Trabajo; Vol. 28 Núm. 3
dc.titleMipomersen in Familial Hypercholesterolemia: an update on health-related quality of life and patient-reported outcomeses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersion
Archivos
Colecciones
Artículo